Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Obese or Overweight Healthy Volunteers Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

NCT07476118
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Brenipatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pistachio Snacking and Metabolic Flexibility

NCT07340125
View directory record Official record
Conditions
Overweight (BMI > 25), Obese But Otherwise Healthy Participants, Overweight or Obese, Obese Patients (BMI ≥ 30 kg/m²), Poor Sleep Quality, Healthy Participants, Physically Inactive
Interventions
Pistachio
Other
Lead sponsor
University of South Carolina
Other
Eligibility
25 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

NCT04839393
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 25, 2026, 7:33 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

NCT06945419
View directory record Official record
Conditions
Healthy, Overweight, Obesity, Type 2 Diabetes
Interventions
LY4086940, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

NCT06845202
View directory record Official record
Conditions
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
Interventions
ALN-4324, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
7
States / cities
Montclair, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

NCT06440980
View directory record Official record
Conditions
Healthy, Obese, Overweight, Obesity
Interventions
Orforglipron
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
7
States / cities
Anaheim, California • Los Alamitos, California • Daytona Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

NCT07446439
View directory record Official record
Conditions
Nausea and Vomiting, Obesity
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity

NCT07232732
View directory record Official record
Conditions
Healthy, Obesity, Overweight
Interventions
LY3549492
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

NCT07514260
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Placebo for ABBV-295
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects

NCT02229214
View directory record Official record
Conditions
Obesity
Interventions
Qsymia, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese

NCT06132841
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 142 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT07511205
View directory record Official record
Conditions
Healthy Participants, Obesity
Interventions
AZD1043, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

NCT05762471
View directory record Official record
Conditions
Overweight or Obesity, Type2 Diabetes Mellitus
Interventions
GSBR-1290, Placebo
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anaheim, California • Chula Vista, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

NCT03385369
View directory record Official record
Conditions
Safety, Healthy Subjects
Interventions
MEDI0382, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jun 25, 2026, 7:33 PM EDT
Completed No phase listed Observational

Stereophotogrammetry of the Torso in Healthy Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity

NCT01352949
View directory record Official record
Conditions
Bone Diseases, Obesity, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

NCT05511025
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Placebo, Acetaminophen
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

NCT07152002
View directory record Official record
Conditions
Overweight or Obesity, Healthy
Interventions
LY4064912, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Los Alamitos, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT07013643
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight

NCT07294898
View directory record Official record
Conditions
Obesity, Overweight
Interventions
KAI-7535
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives

NCT07414784
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

NCT00665665
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC 0070-0002-0182, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

NCT06804603
View directory record Official record
Conditions
Obesity
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jun 25, 2026, 7:33 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity

NCT07437079
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC6989-0001 A, Placebo (NNC6989-0001 A)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Jun 25, 2026, 7:33 PM EDT